Results:
A 2-3 fold increase in atrial PUFA levels were seen in the CHF-PUFA group. PUFA prevented the development of CHF related left atrial enlargement but not left ventricular or atrial dysfunction. Atrial ERP was significantly lower in the CHF-PUFA group but ERP heterogeneity was unchanged. In addition, PUFA suppressed atrial conduction abnormalities seen in CHF of slowed/heterogeneous conduction and prolonged P wave duration. Duration of Induced AF episodes in CHF-PUFA was shorter although AF inducibility was unaltered.
Conclusions:
In this ovine CHF study, chronic PUFA use protected against adverse atrial remodeling by preventing atrial enlargement and conduction abnormalities leading to shorter AF episodes despite lower ERP. The anti-arrhythmic effects of PUFA in CHF require further studies. 
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